62 articles · page 5 of 6
Small molecule drugs have been the norm for much of medicine’s history. Only in the past decade has there been a rise in large molecule drugs which also obtained FDA approval. When it comes to the world of pharmaceuticals, they are divided into two…
The pandemic we just went through was one of the examples of how important is the patent system in strengthening the public health. Already many vaccines and medicines have been created thanks to this system and people nowadays live significantly longer…
Global health care spending is predicted to reach $10 trillion USD during 2022 with almost 30% of it belonging to the USA. It might sound like a good industry to be in, but keep in mind that the costs of developing a new drug range from $300 million up to…
Earlier in August, we released our second ANDA Litigation Intelligence Report. We analyzed all parties involved in Hatch-Waxman cases and ranked the top law firms and attorneys based on their activity and performance. Today we will shed some light on the…
In late August, we released our second annual ANDA Litigation Intelligence Report where we evaluated all stakeholders in Hatch-Waxman cases including ANDA attorneys, local counsel, law firms, pharmaceutical companies, and judges. Today’s insight will…
A couple of weeks ago we released our second annual ANDA Litigation Intelligence Report where we covered the rankings, statistics, and comprehensive analysis of ANDA and Hatch-Waxman stakeholders. We couldn't help but notice the decline in ANDA filing…
Last week we released our first ANDA/Hatch-Waxman Litigation Intelligence Report . Similar to our other IP Insight reports, this time we ranked the top ANDA firms and litigators based on activity and performance. Our research team analyzed the outcome of…
This morning we released our first ANDA Litigation Intelligence Report . For the first time, we ranked all attorneys and law firms by their activity and performance for Hatch-Waxman litigation. Our research team analyzed the outcome of 976 ANDA cases filed…
Senator Orrin Hatch (R-UT) recently introduced a bill titled the “ Hatch-Waxman Integrity Act of 2018 ” (HWIA). Sen. Hatch suggests that the HWIA will (i) “restore the careful balance the Hatch-Waxman Act struck to incentivize generic…
In a recent development with the ongoing complex litigation involving Janssen Biotech’s arthritis biologic medicine Remicade (infliximab) and Celltrion’s biosimilar,(1) Celltrion’s partner Pfizer has filed a suit against Janssen’s…
Written by Daniel A. Kamkar and Agnes Juang, Ph.D. Janssen Biotech Inc. and Celltrion Healthcare have taken the next step over Janssen’s blockbuster arthritis biologic medicine Remicade (infliximab) and Celltrion’s biosimilar, as required by…
In Intendis v Glenmark , the Federal Circuit affirmed a finding of infringement under the doctrine of equivalents based on statements made by Glenmark to the FDA. The issue was whether isopropyl myristate in Glenmark’s formulation was equivalent to…
